Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pediatr ; 201: 147-153, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30041936

RESUMEN

OBJECTIVE: To determine whether perinatal smoking exposure is associated with gastroesophageal reflux (GER)-related changes in sleep-wakefulness states in neonates. STUDY DESIGN: Thirty-one neonates, referred for the investigation of suspected GER, were recruited and underwent multichannel impedance-pH monitoring and synchronized 8- to 12-hour polysomnography. The infants' exposure to tobacco smoke was estimated by means of a urine cotinine assay. The total number, frequency (h-1), and mean duration (minutes) of GER-pH (reflux events detected by the pH electrode only) and GER-imp (reflux events with bolus movement detected by impedance) events were determined. Intergroup differences (smoking-exposed group vs nonexposed group) were probed with nonparametric, unpaired Mann-Whitney U tests. A χ2 test was used to assess a possible intergroup difference in bolus retrograde migration during GER-imp events. RESULTS: According to the urine cotinine assay, 21 of the 31 neonates had been exposed to cigarette smoke during the perinatal period. The number (and frequency) of GER-imp was significantly greater (P = .016) in the exposed group (29 [0-90]) than in the nonexposed group (12 [2-35]). Migration of the esophageal bolus from the distal segment to the most proximal segment was significantly more frequent (P = .016) in the exposed group (83% of GER) than in the nonexposed group (41%). The GER pattern associated with smoking exposure was particularly obvious during Rapid eye movement sleep. CONCLUSIONS: The more frequent occurrence and greater proximal migration of GER-imp in the smoking-exposed group (especially during rapid eye movement sleep) may have clinical relevance. Smoking exposure is a preventable risk factor for limiting the occurrence of GER in neonates.


Asunto(s)
Esófago/fisiopatología , Reflujo Gastroesofágico/fisiopatología , Exposición Materna/efectos adversos , Sueño/fisiología , Fumar/efectos adversos , Vigilia/fisiología , Impedancia Eléctrica , Esófago/metabolismo , Femenino , Reflujo Gastroesofágico/metabolismo , Humanos , Concentración de Iones de Hidrógeno , Recién Nacido , Masculino , Polisomnografía
2.
J Pediatr ; 153(5): 663-6, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18589449

RESUMEN

OBJECTIVES: To determine whether oral domperidone is associated with QT interval prolongation and ventricular arrhythmia and to identify factors that can influence these effects. STUDY DESIGN: An electrocardiogram was performed before and after oral administration of domperidone in 31 neonates or infants classified into 3 groups according to gestational age. RESULTS: Oral domperidone is associated with QTc prolongation except in infants with a gestational age less than 32 weeks of amenorrhea (P < .005). Mean QTc prolongation was 14 msec. On univariate analysis, oral domperidone-induced QTc prolongation was correlated with gestational age, birth weight, and elevated serum potassium. On multivariate analysis, after adjustment for gestational age, serum potassium was the only factor independently associated with interval QT prolongation during treatment. No ventricular arrhythmias were observed. CONCLUSIONS: This study shows a significant association between oral domperidone therapy and QTc prolongation. Two risk factors were identified: advanced gestational age and serum potassium at the upper limit of normal. It is recommended that measurement of the QT interval be done before and after oral domperidone therapy.


Asunto(s)
Domperidona/efectos adversos , Domperidona/farmacología , Síndrome de QT Prolongado/tratamiento farmacológico , Síndrome de QT Prolongado/etiología , Administración Oral , Arritmias Cardíacas/diagnóstico , Antagonistas de Dopamina/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Reflujo Gastroesofágico/tratamiento farmacológico , Edad Gestacional , Humanos , Lactante , Recién Nacido , Contracción Miocárdica/efectos de los fármacos , Potasio/sangre , Riesgo , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA